Journal article
Combination phentermine and topiramate extended release in the management of obesity
Expert opinion on pharmacotherapy, v 16(8), pp 1263-1274
01 Jun 2015
PMID: 25958964
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Introduction: Losing ≥ 5% of initial weight improves quality of life and risk factors for cardiovascular disease (CVD) in obese individuals. Lifestyle modification, the cornerstone of weight reduction, may be complemented by pharmacotherapy. In 2012, the FDA approved the combination of phentermine and topiramate extended release (ER) for chronic weight management, as an adjunct to lifestyle modification.Areas covered: This review examines the safety and efficacy of phentermine-topiramate ER, as determined by randomized controlled trials (RCTs). A preliminary study confirmed the benefit of combining the two medications for improving weight loss and reducing adverse effects, as compared to using equivalent-dose monotherapy alone.Expert opinion: Across RCTs, groups prescribed phentermine 15 mg/topiramate ER 92 mg lost an average of 10% of initial weight, ∼ 8% more than placebo and 2% more than phentermine 7.5 mg/topiramate 46 mg. Weight loss reduced the risk of developing type 2 diabetes and improved CVD risk factors. Phentermine-topiramate ER, however, was associated with increased heart rate, the clinical significance of which is being investigated in an FDA-required CVD outcomes study. The medication also must be used with caution in women of child-bearing age because of an increased risk to infants of oral cleft.
Metrics
Details
- Title
- Combination phentermine and topiramate extended release in the management of obesity
- Creators
- Nasreen Alfaris - University of PennsylvaniaAlyssa M Minnick - University of PennsylvaniaChristina M Hopkins - University of PennsylvaniaRobert I Berkowitz - University of PennsylvaniaThomas A Wadden - University of Pennsylvania
- Publication Details
- Expert opinion on pharmacotherapy, v 16(8), pp 1263-1274
- Publisher
- Informa UK, Ltd
- Number of pages
- 12
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- WELL Center
- Web of Science ID
- WOS:000354214700014
- Scopus ID
- 2-s2.0-84929166172
- Other Identifier
- 991022017429804721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Pharmacology & Pharmacy